22157.jpg
Global Enzyme Inhibitor Markets, Analysis & Forecasts, 2016-2021, 2021-2026F, 2031F: Focus on PPIs, Protease, Reverse Transcriptase, Aromatase, Kinase, Neuraminidase, & Statins
18 oct. 2022 06h33 HE | Research and Markets
Dublin, Oct. 18, 2022 (GLOBE NEWSWIRE) -- The "Enzyme Inhibitor Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.The global enzyme inhibitor market is expected...
Geron-logo-black-xsmall.png
Geron Reports Four Imetelstat Data Presentations at Virtual Edition of the European Hematology Association (EHA) Annual Congress
12 juin 2020 08h30 HE | Geron Corporation
For the IMerge Phase 2 clinical trial, meaningful and durable transfusion independence reported with a new 1-year TI rate, indicating potential disease-modifying activity of imetelstat treatmentFor...
Geron-logo-black-xsmall.png
Geron to Present at Needham Virtual Healthcare Conference
08 avr. 2020 16h30 HE | Geron Corporation
MENLO PARK, Calif., April 08, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to present a...
Geron-logo-black-xsmall.png
Geron Corporation Reports Fourth Quarter and Full Year 2019 Financial Results and 2020 Milestones
12 mars 2020 16h05 HE | Geron Corporation
MENLO PARK, Calif., March 12, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat,...
Geron-logo-black-xsmall.png
Geron Announces First Patient Dosed in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes
10 oct. 2019 17h30 HE | Geron Corporation
MENLO PARK, Calif., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that the first patient has been dosed in the IMerge Phase 3 clinical trial to evaluate...
Geron-logo-black-xsmall.png
Geron Announces Fast Track Designation Granted to Imetelstat for Relapsed/Refractory Myelofibrosis
30 sept. 2019 16h19 HE | Geron Corporation
MENLO PARK, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation...
Geron-logo-black-xsmall.png
Geron to Present at 2019 Cantor Global Healthcare Conference
26 sept. 2019 16h18 HE | Geron Corporation
MENLO PARK, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to present a...
Geron-logo-black-xsmall.png
Geron Starts Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes
08 août 2019 08h08 HE | Geron Corporation
MENLO PARK, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced the opening of patient screening and enrollment for the Phase 3 portion of IMerge to evaluate...
Geron-logo-black-xsmall.png
Geron Corporation Reports Second Quarter 2019 Financial Results and Recent Events
01 août 2019 16h05 HE | Geron Corporation
MENLO PARK, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the second quarter ended June 30, 2019, and recent events. The Company...
Geron-logo-black-xsmall.png
Geron to Announce Second Quarter Financial Results on August 1, 2019
25 juil. 2019 08h00 HE | Geron Corporation
MENLO PARK, Calif., July 25, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that it will release its second quarter 2019 financial results after the market closes on...